|
|
|
| home > epc > winter 2002 > the outlook for central nervous system drug development |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
t is estimated that as many as 1.5 billion people worldwide are suffering at any given time from some type of central nervous system (CNS) disorder and therefore there is a strong demand from patients for effective treatments (1). In 2001, global sales of CNS products reached US$43 billion, an increase of 17% over the previous year (2). This represented the highest increase of all the top therapeutic categories (2). Pharmaceutical companies have taken note of the demand for CNS medicines and have invested heavily in this area. However, progress in developing new treatments for these complex disorders is dependent on identifying the relevant factors to each disorder and many of these disorders are still poorly understood (1).
The Health Burden of CNS Disorders
Studies by the World Health Organization (WHO) have shown that the impact of CNS disorders on society has been seriously underestimated by traditional health care approaches, as these focused on deaths and not disability (1, 3). In the 1990s, WHO global figures revealed that CNS conditions accounted for 28% of all years lived with a disability (YLDs) compared with 1.4% of all deaths and 1.1% of years of life lost (1, 3). The predominance of these conditions is not just restricted to the most developed countries and therefore there is a global demand for effective medicines treating CNS disorders.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Faiz Kermani, Budgets, Proposals and Marketing Executive, and Stuart McGuire, Business Development Executive at Chiltern International
Dr Faiz Kermani currently works in Business Development at Chiltern International, a CRO, where his role covers bids, proposals and marketing. Previously, Faiz worked in Business Development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He has also worked as a research analyst for Danish health care consultancy Informedica A/S, focusing on global pharmaceutical pricing and parallel importation.
He holds a PhD in immunopharmacology from St. Thomas' Hospital in London and a First Class Honours Degree in Pharmacology with Toxicology from King's College, London. .
Stuart McGuire has worked as a Business Development Executive at Chiltern International for two years.
After graduating in Chemistry from the University of Surrey in 1999, he worked in malaria research before moving into marketing. One of Stuart's current areas of interest at Chiltern is R&D within the Japanese pharmaceutical industry.
|
|
|
|
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
Firstan Ltd are first to achieve the new Pharmaceutical PS9000:2011 quality standard
Firstan Ltd, the UK’s leading independently owned Pharmaceutical and Food Carton producer have become the first UK Packaging company to achieve the new Pharmaceutical PS9000:2011 quality standard for its Healthcare Division. This standard was published in September 2011 in consultation with industry suppliers, pharmaceutical companies and other stakeholder organisations. Firstan have held the Pharmaceutical accreditation for almost 20 years.
More info >> |
|
|
